CSL (OTCMKTS:CSLLY) Shares Gap Up – Still a Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $17.43, but opened at $18.77. CSL shares last traded at $18.96, with a volume of 4,785 shares.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CSLLY shares. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Canaccord Genuity Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research lowered shares of CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Citigroup lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Royal Bank Of Canada lowered shares of CSL from a “moderate buy” rating to a “hold” rating in a report on Wednesday, February 11th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

CSL Trading Up 5.3%

The stock’s 50-day simple moving average is $20.88 and its 200 day simple moving average is $40.39. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.